Letter by Sueta et al Regarding Article, “Urgent Need to Measure Effects of Direct Oral Anticoagulants”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article in which Weitz and Eikelboom1 advocated the necessity of measuring the effects of direct oral coagulants (DOACs). We strongly agree with their opinions. It is true that no specific tool monitors the anticoagulant effects of DOACs and that some patients suffer from bleeding complications related to exceedingly high concentrations of DOACs in the blood. Routine tests, such as the prothrombin time and the activated partial thromboplastin time, can be problematic for monitoring the anticoagulant effects of all DOACs. Changes in prothrombin time and activated partial thromboplastin time levels after DOAC treatment might not be large enough …